Medication-induced Uveitis: An Update

Overview

Journal J Ophthalmic Vis Res

Specialty Ophthalmology

Date 2021 Feb 1

PMID 33520131

Citations 3

Authors

Kashif M Iqbal

Madeline W Hay

Parisa Emami-Naeini

Affiliations

Soon will be listed here.

Abstract

Drug-induced uveitis is an uncommon but important cause of ocular inflammation. Uveitis can be seen in association with various systemic, topical, and intraocular medications. In this article, we review common medications associated with uveitis. Most cases of drug-induced uveitis resolve with termination of the suspected medication with or without administration of topical or systemic steroids. It is important for clinicians to readily identify medications that may cause uveitis in order to provide rapid treatment, avoid consequences of longstanding inflammation, and prevent costly and excessive laboratory testing.

Citing Articles

Antiviral Agents for Preventing Cytomegalovirus Disease in Recipients of Hematopoietic Cell Transplantation.

Jaing T, Wang Y, Chiu C Viruses. 2024; 16(8).

PMID: 39205242 PMC: 11359103. DOI: 10.3390/v16081268.

Pediatric uveitis: Role of the pediatrician.

Shivpuri A, Turtsevich I, Solebo A, Compeyrot-Lacassagne S Front Pediatr. 2022; 10:874711.

PMID: 35979409 PMC: 9376387. DOI: 10.3389/fped.2022.874711.

A Review of Systemic Biologics and Local Immunosuppressive Medications in Uveitis.

Mehta N, Emami-Naeini P J Ophthalmic Vis Res. 2022; 17(2):276-289.

PMID: 35765634 PMC: 9185190. DOI: 10.18502/jovr.v17i2.10804.

References

Drlica K, Zhao X . DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997; 61(3):377-92. PMC: 232616. DOI: 10.1128/mmbr.61.3.377-392.1997. View

Sharma A, Kumar N, Kuppermann B, Bandello F, Loewenstein A . Biotherapeutics and immunogenicity: ophthalmic perspective. Eye (Lond). 2019; 33(9):1359-1361. PMC: 7002711. DOI: 10.1038/s41433-019-0434-y. View

Nichols C . Mycobacterium avium complex infection, rifabutin, and uveitis--is there a connection?. Clin Infect Dis. 1996; 22 Suppl 1:S43-7; discussion S47-9. DOI: 10.1093/clinids/22.supplement_1.s43. View

Cellini M, Caramazza R, Bonsanto D, Bernabini B, Campos E . Prostaglandin analogs and blood-aqueous barrier integrity: a flare cell meter study. Ophthalmologica. 2004; 218(5):312-7. DOI: 10.1159/000079472. View

Moorthy R, Moorthy M, Cunningham Jr E . Drug-induced uveitis. Curr Opin Ophthalmol. 2018; 29(6):588-603. DOI: 10.1097/ICU.0000000000000530. View

Wells J, Glassman A, Ayala A, Jampol L, Bressler N, Bressler S . Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016; 123(6):1351-9. PMC: 4877252. DOI: 10.1016/j.ophtha.2016.02.022. View

Cunningham E, Moorthy R, Zierhut M . Immune Checkpoint Inhibitor-Induced Uveitis. Ocul Immunol Inflamm. 2020; 28(6):847-849. DOI: 10.1080/09273948.2020.1801286. View

Ostheimer T, Burkholder B, Leung T, Butler N, Dunn J, Thorne J . Tattoo-associated uveitis. Am J Ophthalmol. 2014; 158(3):637-43.e1. DOI: 10.1016/j.ajo.2014.05.019. View

Cunningham Jr E . Uveitis in HIV positive patients. Br J Ophthalmol. 2000; 84(3):233-5. PMC: 1723394. DOI: 10.1136/bjo.84.3.233. View

10.

Tilden M, Rosenbaum J, Fraunfelder F . Systemic sulfonamides as a cause of bilateral, anterior uveitis. Arch Ophthalmol. 1991; 109(1):67-9. DOI: 10.1001/archopht.1991.01080010069035. View

11.

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

12.

Majjad A, Bezza A, Biyi A, El Ochi M, Maghraoui A . Pulmonary Sarcoidosis following Etanercept Treatment for Ankylosing Spondylitis: A Case Report and Review of the Literature. Case Rep Rheumatol. 2018; 2018:9867248. PMC: 5828086. DOI: 10.1155/2018/9867248. View

13.

Dalvin L, Shields C, Orloff M, Sato T, Shields J . CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. Retina. 2018; 38(6):1063-1078. DOI: 10.1097/IAE.0000000000002181. View

14.

Jabs D, Nussenblatt R, Rosenbaum J . Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005; 140(3):509-16. PMC: 8935739. DOI: 10.1016/j.ajo.2005.03.057. View

15.

Antonia S, Lopez-Martin J, Bendell J, Ott P, Taylor M, Eder J . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5. View

16.

Sharma A, Kumar N, Parachuri N, Sharma R, Bandello F, Kuppermann B . Brolucizumab and immunogenicity. Eye (Lond). 2020; 34(10):1726-1728. PMC: 7608337. DOI: 10.1038/s41433-020-0853-9. View

17.

Lim L, Fraunfelder F, Rosenbaum J . Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007; 56(10):3248-52. DOI: 10.1002/art.22918. View

18.

Day S, Acquah K, Mruthyunjaya P, Grossman D, Lee P, Sloan F . Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011; 152(2):266-72. PMC: 3143287. DOI: 10.1016/j.ajo.2011.01.053. View

19.

Anquetil C, Salem J, Lebrun-Vignes B, Touhami S, Desbois A, Maalouf G . Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database. J Autoimmun. 2020; 111:102454. DOI: 10.1016/j.jaut.2020.102454. View

20.

Winkler N, Fautsch M . Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2013; 30(2-3):102-9. PMC: 3991965. DOI: 10.1089/jop.2013.0179. View